Details of the Drug

General Information of Drug (ID: DMJLZ8T)

Drug Name

CHT-25

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Phase 1	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 2 receptor alpha (IL2RA)	TT10Y9E	IL2RA_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.